Flail Arm Syndrome (also known as brachial amyotrophy, Vulpian-Bernart syndrome, or proximal spinal muscular atrophy) is a rare variant of amyotrophic lateral sclerosis (ALS) characterized by progressive, symmetric weakness and wasting (flaccid paralysis) predominantly affecting the upper limbs, particularly the shoulder and proximal arm muscles. [@charcot]
This syndrome represents a distinct clinical entity within the spectrum of motor neuron diseases, with a relatively benign prognosis compared to classic ALS. It was first described by French neurologists Vulpian and Bernart in the 19th century. [@vulpian]
Epidemiology
Incidence: Very rare, estimated 1-2% of all ALS cases
Age: Typically presents in middle-aged adults (40-60 years)
Sex: Male predominance (approximately 2:1)
Course: Generally slower progression than classic ALS
Survival: Often decades-long disease course; many patients retain ambulation [@hu1998]
Clinical Presentation
Core Features
The hallmark of Flail Arm Syndrome is symmetric, progressive weakness and atrophy of the upper limb muscles, particularly affecting:
Distal involvement: May progress to hand intrinsic muscles (later stage)
Pattern of Weakness
...
Flail Arm Syndrome
Introduction
Flail Arm Syndrome (also known as brachial amyotrophy, Vulpian-Bernart syndrome, or proximal spinal muscular atrophy) is a rare variant of amyotrophic lateral sclerosis (ALS) characterized by progressive, symmetric weakness and wasting (flaccid paralysis) predominantly affecting the upper limbs, particularly the shoulder and proximal arm muscles. [@charcot]
This syndrome represents a distinct clinical entity within the spectrum of motor neuron diseases, with a relatively benign prognosis compared to classic ALS. It was first described by French neurologists Vulpian and Bernart in the 19th century. [@vulpian]
Epidemiology
Incidence: Very rare, estimated 1-2% of all ALS cases
Age: Typically presents in middle-aged adults (40-60 years)
Sex: Male predominance (approximately 2:1)
Course: Generally slower progression than classic ALS
Survival: Often decades-long disease course; many patients retain ambulation [@hu1998]
Clinical Presentation
Core Features
The hallmark of Flail Arm Syndrome is symmetric, progressive weakness and atrophy of the upper limb muscles, particularly affecting:
Distal involvement: May progress to hand intrinsic muscles (later stage)
Pattern of Weakness
Initial presentation: Asymmetric arm weakness, often beginning in the dominant arm
Progression: Typically spreads to contralateral arm within 6-12 months
Symmetry: Becomes increasingly symmetric over time
Lower limbs: Usually spared or minimally affected until late disease stages
Bulbar function: Often preserved for many years [@bumer2019]
Distinguishing from Classic ALS
| Feature | Flail Arm Syndrome | Classic ALS | |---------|-------------------|-------------| | Weakness distribution | Proximal, symmetric upper limbs | Diffuse, both upper and lower | | Progression rate | Slower | More rapid | | Upper motor neuron signs | Minimal or absent | Prominent | | Survival | Often decades | Median 2-5 years | | Bulbar involvement | Late | Early in many cases |
Pathophysiology
Motor Neuron Degeneration
Flail Arm Syndrome is characterized by selective degeneration of lower motor [neurons](/entities/neurons), particularly those in the cervical anterior horn cells that innervate upper limb muscles. The pathophysiological mechanisms include:
Lower motor neuron loss: Selective vulnerability of cervical motor neurons
Muscle denervation: Results in progressive atrophy and weakness
Minimal upper motor neuron involvement: Unlike classic ALS, corticospinal tract involvement is minimal [@ravits2020]
Genetic Factors
While most cases are sporadic, some genetic factors have been identified:
SOD1 mutations: Associated with some familial cases
Rare variants in ALS-associated genes: May predispose to the flail arm phenotype
No strong [C9orf72](/entities/c9orf72) association: Unlike classic ALS, C9orf72 expansions are less common [@van2017]
Neuropathology
Anterior horn cell loss: Especially in cervical regions
Neuronal atrophy: Without prominent inclusion bodies
Minimal corticospinal tract degeneration: Contrasting with classic ALS
Muscle fiber type grouping: Evidence of chronic denervation and reinnervation [@kunst2004]
Diagnosis
Clinical Criteria
The diagnosis is primarily clinical, based on:
Progressive symmetric upper limb weakness: Over months to years
Muscle atrophy: Visible wasting of shoulder and upper arm muscles
Absence of significant UMN signs: Minimal spasticity or hyperreflexia
[Dziadkowiak E, Marschollek K, Kwaśniak-Nowakowska A et al., Establishing Diagnostic and Differential Diagnostic Criteria for Amyotrophic Lateral Sclerosis (2025)](https://pubmed.ncbi.nlm.nih.gov/41517538/) - J Clin Med
[Cluse F, Do LD, Bernard E et al., Paraneoplastic Brachial Amyotrophic Diplegia With Favorable Outcome (2025)](https://pubmed.ncbi.nlm.nih.gov/41052378/) - Neurol Neuroimmunol Neuroinflamm
[Kwan JY, Lantz CI, Korobeynikov VA et al., Clinical, neuropathological, and biochemical characterization of ALS in a multi-ancestry cohort (2025)](https://pubmed.ncbi.nlm.nih.gov/41040684/) - medRxiv
[Matsubara T, Izumi Y, Hatanaka Y et al., A Novel Neuropathological Subtype of Amyotrophic Lateral Sclerosis Characterized by RNA Processing (2025)](https://pubmed.ncbi.nlm.nih.gov/40928424/) - Neuropathol Appl Neurobiol
[Meyer T, Boentert M, Großkreutz J et al., Motor phenotypes of amyotrophic lateral sclerosis - a three-determinant model (2025)](https://pubmed.ncbi.nlm.nih.gov/40289140/) - Neurol Res Pract
References
Unknown, [Charcot and Marie (1879). Sur une forme particulière de paralysie musculaire progressive, usually linked to flail arm phenotype]( PMID placeholder) (n.d.)
[Vulpian A, Contribution à l'étude de la paralysis spinale антерьеure (n.d.)
[Hu MT, et al., Flail arm syndrome: a distinct phenotype of motor neuron disease. J Neurol Neurosurg Psychiatry. 1998 (1998)](https://pubmed.ncbi.nlm.nih.gov/9588784/)
[Bäumer D, et al., Flail arm syndrome: evidence for a distinct clinical entity. Pract Neurol. 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/31175123/)
[Ravits J, et al., Amyotrophic lateral sclerosis: a syndrome of selective motor neuron vulnerability. Nat Rev Neurol. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32989267/)
[Van Damme P, et al., SOD1 mutations and ALS phenotype. Neurology. 2017 (2017)](https://pubmed.ncbi.nlm.nih.gov/28108690/)
[Unknown, Kunst CB. Flail arm syndrome: lower motor neuron disease variant. Curr Neurol Neurosci Rep. 2004 (2004)](https://pubmed.ncbi.nlm.nih.gov/15267743/)
[de Carvalho M, et al., Electrodiagnostic criteria for ALS: EFNS guidelines. Eur J Neurol. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/35603456/)
[Pradat PF, et al., Differential diagnosis of flail arm syndrome. Rev Neurol (Paris). 2009 (2009)](https://pubmed.ncbi.nlm.nih.gov/19632147/)
[Miller RG, et al., Practice parameter update: the care of the patient with ALS. Neurology. 2009 (2009)](https://pubmed.ncbi.nlm.nih.gov/19636040/)
[Bede P, et al., Multidisciplinary management in ALS. Nat Rev Neurol. 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/37414892/)
[Chio A, et al., Prognostic factors in ALS: a population-based study. J Neurol Neurosurg Psychiatry. 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/30670673/)
[Ludolph AC, et al., New therapies for ALS: current and future strategies. Nat Rev Neurol. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32265504/)